VIDEO: OlympiA trial 'very exciting in the world of genetics' in breast cancer
Click Here to Manage Email Alerts
In this video, Holly Pederson, MD, assistant professor of medicine in the Cleveland Clinic Lerner College of Medicine of Case Western University, spoke with Healio about results from the OlympiA trial presented at ASCO 2021.
In the randomized, double-blind, phase 3 study, researchers determined that patients with germline BRCA1/2 mutations and HER2-negative high-risk early breast cancer who received the PARP inhibitor olaparib after primary local treatment with adjuvant chemotherapy or neoadjuvant chemotherapy had significantly improved invasive disease-free survival and distant disease-free survival as well as acceptable toxicity.
“The OlympiA trial is very exciting in the world of genetics, in terms of the use of PARP inhibitors in the adjuvant treatment setting, and not just the metastatic breast cancer setting,” she said.
Collapse
Read more about
Click Here to Manage Email Alerts